Six Open Clinical Trials That Are Expanding Our Understanding of Immunotherapies


Study: Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma (NCT01415752)

Sponsor: Eastern Cooperative Oncology Group

Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and help kill them or carry cancer-killing substances to them. Others interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as bendamustine hydrochloride, also work in different ways to kill cancer cells or stop them from dividing. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Lenalidomide may stop the growth of mantle cell lymphoma by blocking blood flow to the cancer. It is not yet known whether giving rituximab together with bendamustine and bortezomib is more effective than rituximab and bendamustine, followed by rituximab alone or with lenalidomide in treating mantle cell lymphoma.

Federal Study Locations (426 total): Kansas City VAMC, VA New Jersey Health Care System, East Orange


Recommended Reading

Glimmer of promise for nivolumab in neoadjuvant NSCLC therapy
Federal Practitioner
Pembrolizumab boosts response but not survival in small study of advanced NSCLC
Federal Practitioner
Change in end-of-life cancer care imperative
Federal Practitioner
Pembrolizumab ‘new standard of care’ in advanced PD-L1-rich NSCLC
Federal Practitioner
Nivolumab + ipilimumab induced fulminant, fatal myocarditis
Federal Practitioner